Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the MASH market include the anticipated launch of new pipeline agents, particularly GLP-1RA drugs like semaglutide, increased prevalence of MASH, ...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatohepatitis (MASH): Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ...

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Novo Nordisk (NYSE:NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk announced new post hoc analysis data from the ESSENCE Phase 3 trial regarding the ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...

The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...